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Abstract AKXD recombinant inbred (RI) strains develop
a variety of leukemias and lymphomas due to somatically
acquired insertions of retroviral DNA into the genome of
hematopoetic cells that can mutate cellular proto-onco-
genes and tumor suppressor genes. We generated a new set
of tumors from nine AKXD RI strains selected for their
propensity to develop B-cell tumors, the most common
type of human hematopoietic cancers. We employed a PCR
technique called viral insertion site ampliﬁcation (VISA) to
rapidly isolate genomic sequence at the site of provirus
insertion. Here we describe 550 VISA sequence tags
(VSTs) that identify 74 common insertion sites (CISs), of
which 21 have not been identiﬁed previously. Several
suspected proto-oncogenes and tumor suppressor genes lie
near CISs, providing supportive evidence for their roles in
cancer. Furthermore, numerous previously uncharacterized
genes lie near CISs, providing a pool of candidate disease
genes for future research. Pathway analysis of candidate
genes identiﬁed several signaling pathways as common and
powerful routes to blood cancer, including Notch, E-pro-
tein, NFjB, and Ras signaling. Misregulation of several
Notch signaling genes was conﬁrmed by quantitative RT-
PCR. Our data suggest that analyses of insertional muta-
genesis on a single genetic background are biased toward
the identiﬁcation of cooperating mutations. This tumor
collection represents the most comprehensive study of the
genetics of B-cell leukemia and lymphoma development in
mice. We have deposited the VST sequences, CISs in a
genome viewer, histopathology, and molecular tumor typ-
ing data in a public web database called VISION (Viral
Insertion Sites Identifying Oncogenes), which is located at
http://www.mouse-genome.bcm.tmc.edu/vision.
Introduction
The oncogenic transformation of a cell requires several
mutations conferring abnormal properties that may include
independence from the requirement for growth stimulatory
signals, loss of sensitivity to growth inhibitory signals, the
acquisition of unlimited proliferative capacity, suppression
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DOI 10.1007/s00335-007-9060-2of apoptotic signals, and the successful evasion of immune
responses (Dunn et al. 2002; Hanahan and Weinberg 2000).
A common feature of human leukemias and lymphomas is
nonrandom, somatically acquired chromosomal transloca-
tions and inversions that are often diagnostic criteria of
speciﬁc subtypes of malignancies. It has been estimated
that 65% of all cases of human acute leukemias involve
chromosomal abnormalities (Look 1997). Oncogenic
translocations frequently act by upregulation of proto-
oncogenes or inactivation of tumor suppressor genes
(TSGs).
In the mouse, loci involved in the onset and progression
of hematologic malignancies have been identiﬁed primarily
by the isolation of common proviral insertion sites (CISs).
Slow-transforming retroviruses cause a subset of reinfected
cells to become oncogenic by altering the expression of
genes near their insertion sites in a manner reminiscent of
translocations in human malignancy. Aberrant gene
expression can be caused by placing the affected locus
under the direct control of viral long terminal repeat (LTR)
promoters, long-range enhancer activity of the LTRs, dis-
ruption of the affected locus by proviral insertion within
coding sequences, or local alterations of chromatin. The
rare cases in which an insertion affects the expression of a
proto-oncogene or TSG can result in the neoplastic trans-
formation and clonal expansion of the affected cell.
Because proviral insertions are near the loci whose
expression they alter, these insertions can be used as a
molecular tag to isolate and identify affected loci. Identi-
ﬁcation of these loci can be important for understanding the
pathogenesis of human neoplasms because genes proximal
to viral insertion sites in mouse tumors are often deregu-
lated in human blood cancers, highlighting the applicability
of slow-transforming retroviral mutagenesis as a model for
human disease (Erkeland et al. 2006). Systematic surveys
of CISs found in well-established mouse models of lym-
phoid and myeloid malignancies have implicated a wide
range of genes involved in a diversity of cellular functions
as potential oncogenes and TSGs. As with chromosomal
translocations in human leukemia and lymphomas, many
genes implicated in tumor incidence are known to be key
regulators of normal hematopoiesis or have hematopoietic
lineage-speciﬁc expression patterns (Suzuki et al. 2002). In
addition, insertion sites that are commonly found in a
particular class of neoplasia may identify loci whose
altered expression is a common event in the development
of that cancer subtype (reviewed in Jonkers and Berns
1996). The AKXD mouse strains chosen for the present
study were previously found to develop a high incidence of
B-cell lymphomas allowing us to focus our efforts on
understanding the molecular basis underlying the patho-
genesis of the most common human hematopoietic
neoplasms (http://www.seer.cancer.gov).
The AKXD RI strains were generated from crosses of
the T-cell lymphoma-prone AKR/J strain of mice with the
DBA/2J strain of mice to generate 21 highly lympho-
matous strains that vary in tumor incidence and tumor
subtype. High rates of lymphoma correlated with the
presence of transposable MuLV, indicating that MuLV is
the primary mutagen in this model. Seven strains develop
primarily B-cell neoplasms, whereas six develop T-cell,
seven mixed B- and T-cell, and one primarily myeloid
neoplasia (Gilbert et al. 1993). Many other mouse strains
used for studying the molecular genetics of tumor
development develop primarily myeloid disease (Eriksson
et al. 1999; Jonkers et al. 1997; Liao et al. 1997; Moskow
et al. 1995; Nakamura et al. 1996; Shaughnessy et al.
1999; Szymanska et al. 1999; Valk et al. 1997; van
Lohuizen and Berns 1990; for review see Voisin et al.
2006), with the exception of the NFS.V+ strain, which
also develops predominantly B-cell lineage neoplasms
(Hartley et al. 2000). Each of these strains has proven to
be very useful for identifying potential oncogenes and
TSGs involved in the development of lymphoid and
myeloid malignancies.
In this article we describe a new tumor subset from
AKXD mice and perform a complete genomic analysis of
the insertion sites. The use of our novel viral insertion site
ampliﬁcation (VISA) technique permits the rapid
sequence-based identiﬁcation of loci that potentially play
a role in the development of these tumors (Hansen et al.
2000). The VISA approach is based on a technique called
restriction-site PCR (Sarkar et al. 1993), which allows
priming from a single site ﬂanking the provirus with no
prior knowledge of the genomic sequence and does not
require a subcloning step, reducing false-positive detec-
tion. Here we have isolated 550 VISA sequence tags
(VSTs) from screening tumors that developed in 204 mice
from nine AKXD strains. These tags identify 74 CISs, of
which 21 have not previously been identiﬁed, and repre-
sent new candidate proto-oncogenes and TSGs for
lymphoid tumors.
Materials and methods
AKXD mice
Animals from nine AKXD RI strains of mice that develop
either predominantly B-cell or mixed T/B-cell lymphomas
were obtained from The Jackson Laboratory (Bar Harbor,
ME), aged to 18 months, and monitored for signs of illness.
Moribund animals or normal animals at the age of 18
months were autopsied and evaluated. Both normal and
tumor tissues from a single lymphomatous animal was
snap-frozen in liquid nitrogen.
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A portion of each tumor was ﬁxed in 10% formalin and
embedded in parafﬁn. These ﬁxed tumors were analyzed
for histopathology as previously described (Morse et al.
2001) at the Laboratory of Immunopathology at the
National Institute of Allergy and Infectious Diseases at the
National Institutes of Health (Bethesda, MD).
Genomic DNA was extracted from both normal and
tumor tissues as described (Wu et al. 1995) followed by a
single phenol/chloroform extraction and ethanol precipi-
tation (Sambrook et al. 1989). Restriction enzyme-digested
genomic DNAs from tumors were electrophoresed and
transblotted (Sambrook et al. 1989). Membranes were
prehybridized and hybridized as described (Church and
Gilbert 1984). Probes for IgH, IgK, JB1, and JB2 were
described previously (Kronenberg et al. 1985; Mucenski
et al. 1986). Tumors were classiﬁed as B, T, or mixed
lineage based on BCR (IgH and IgK) or TCR (JB1 or JB2)
gene rearrangements. In cases where histopathology and
genomic rearrangements were contradictory, histopathol-
ogy data took precedence in classifying the tumor, but all
information is deposited in the database.
VST identiﬁcation
TheVISAprocedurewasperformedasdescribedpreviously
(Hansen et al. 2000). Brieﬂy, the ampliﬁcation of mouse
genomic DNA ﬂanking proviral insertion elements was
performedinatwo-stepPCR.Theﬁrstroundwasperformed
using a degenerate, restriction-site-speciﬁc primer contain-
ing the M13 sequence and a nested primer (SP1) speciﬁc to
the ecotropic MuLV LTR. The secondround was performed
using 1 ll of ﬁrst-round PCR product as template, a nested
LTR-speciﬁc primer, and the M13F primer. The products of
second-roundPCRwereanalyzedbygelelectrophoresisand
the tumor-speciﬁc VISA products were excised (reducing
endogenous virus detection), puriﬁed, and sequenced
directly. DNA isolated from brain tissue, which is rarely
inﬁltratedbytumorcells,wasusedasacontroltoidentifyall
nontarget ampliﬁcation products such as endogenous pro-
viral insertion sites, internal proviral sequences, or single
primer ampliﬁcation products generated by the restriction-
site-anchored primer. Puriﬁed DNAs were ampliﬁed using
the ABI Prism BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and electrophoresed
on an ABI Model 377 DNA sequencer (Applied Biosys-
tems). Sequences were analyzed using Sequencher software
(Gene Codes Corp., Ann Arbor, MI). Sequences were edited
to remove ambiguous bases and examined for sequence
overlap. As a control for speciﬁcity, each sequence from the
second-round PCR was analyzed to conﬁrm the presence of
the target restriction enzyme (RE) recognition site and viral
LTR sequence. When a single insertion mutation was
ampliﬁed multiple times using different RE primers from a
single tumor, only the longest sequence was designated as a
VISA sequence tag (VST) and was used for further analysis.
Repeat-masked VST sequences were compared using
BLASTn (ftp://ftp.ncbi.nih.gov/blast/executables/) against
the mouse genome assembly (Ensembl release 40
from NCBI assembly m36), which was downloaded
from the Ensembl genome annotation website (ftp://ftp.
ensembl.org/pub/current_mus_musculus/data/fasta/dna/).
The BLAST results were visualized by an in-house-devel-
oped program (VST Visualization) to conﬁrm that the
highest-ranking alignment was the only highly ranked
alignmentandthematchwasnotarepeatsequence.Allvalid
hits from the BLAST results were deposited in our MS-SQL
Serverdatabases.BasedontheinformationfromtheBLAST
results, VSTs were mapped to the mouse genome (http://
www.ensembl.org/Multi/martview), and ﬂanking genes for
each of the VSTs were identiﬁed. All Ensembl annotated
genes within 200 kb of each VST location are displayed in
the VISION database (http://www.mouse-genome.bcm.
tmc.edu/vision).
Calculation of false positives
The proportion of cancers caused by genetic background
versus virus insertion can be differentiated using basic
probability:
Probabilityof aorb ¼ Pa þ Pb ðÞ   Pa   Pb ðÞ
Cancer rate in the absence of transposable virus is 12.5%
(Mucenski et al. 1986); overall AKXD cancer rate (with
transposable virus) is 43% (this article):
43% ¼ 12:5% þ V ðÞ   12:5%   V ðÞ
where V is the cancer rate due to viral insertion and is 39%.
The proportion of cancer that can be attributed to viral
insertion in this study is
V=totalcancerrate ¼ 0:39=0:43 ¼ 91%
Since viral insertion is causative in 91% of cancers and the
viral insertion number in cancers is low, one would expect
a low rate of false positives. The average number of pro-
viral insertions required to cause cancer in this model is
unknown but it must be at least 1 (since viral insertion is
the primary mutagen) and less than 5.5 (average viral
insertions per tumor). This allows us to calculate a range of
true positives that we should expect to recover:
204 tumors * 91% requiring viral insertion * 1–5.5
insertions required to induce cancer = 186–1021 insertions
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500 true positive VSTs recovered
Calculation of degree of saturation
We have used a truncated Poisson distribution to determine
the number of undiscovered alleles from the frequency of
alleles with more than one mutation (f), using the equation:
f ¼ 1   e m   me m ðÞ =1   e m
(Johnsen 2000) where m is mean number of insertions per
locus, f is multiple-hit common insertion loci/total loci
(from above):
f = 46/186 = 0.2473
f = 46/1021 = 0.0451
% undiscovered loci = e
–m = 58–91%
saturation = 1–e
–m = 9–42%
Real-time quantitative RT-PCR (QPCR)
Total RNA was isolated from frozen tumor tissue sam-
ples with RNA-stat (Tel-test Inc., Friendswood, TX).
cDNA was prepared from 2 lg of RNA with the
Superscript II Reverse Transcription Kit (Invitrogen,
Carlsbad, CA) using random hexamers. QPCR primers
were designed using Primer Express (Applied Biosys-
tems) with amplicons spanning exon junctions in most
cases. Optimal concentrations were determined for each
primer pair by running all pairwise combinations of 50-,
300-, and 900-nM primers on wild-type mouse blood,
spleen, or embryo cDNA. Real-time PCR was performed
in the ABI 7000 TaqMan. Applied Biosystems SYBR
Green master mix was used with 1 ll of cDNA/well in
96-well optical plates. PCR cycling conditions were 1 ·
(95 C for 10 min) and 40 · (95 C for 15 sec; 60 C for 1
min), with a dissociation curve performed following
ampliﬁcation.
Results
Screening for cancer loci
A total of 469 male and female mice from nine different
AKXD RI strains that develop primarily B-cell or mixed B/
T-cell leukemia or lymphoma were aged for 18 months.
Although tumor incidence varied by strain, 43% (204/469)
of aged mice developed lymphomas (Table 1). Tumors
were collected, and histopathology was performed to
determine cell type. Somatic recombination of immuno-
globulin (IgH, IgK) and T-cell receptor b-chain genes (JB1
and JB2) was analyzed by Southern blot to further reﬁne
lymphoid cell typing. The combined histologic and
molecular criteria used to determine cell type demonstrate
the high frequency of B-cell lineage neoplasms (48%;
Table 2) (Morse et al. 2001). The molecular cell type,
stage, and nature of each tumor can be found at the
VISION database.
Tumors were screened by the VISA technique to iden-
tify the location of somatic retroviral insertion sites
(Hansen et al. 2000). To avoid redundancy, multiple
sequence tags identiﬁed by different restriction enzyme
primers from a single animal that overlap were edited into
a single VISA sequence tag (VST) representing the longest
unique ﬂanking sequence (Fig. 1A). The fact that our
technique ampliﬁed from the 50 end of the provirus alone
ensured that nonoverlapping tags from a single tumor were
not acquired. From over 3000 sequence tags, a total of 550
nonendogenous VSTs were identiﬁed in tumors that
occurred in 204 animals.
VST sequences were subjected to BLAST against the
Ensembl mouse genome sequence (NCBI m36). After
exclusion of low-scoring matches and repetitive sequence
matches, 468 VSTs yielded single signiﬁcant matches to
the genome. These insertions were analyzed for genomic
clustering to identify CISs (Fig. 1B). CISs representing
endogenous virus loci were identiﬁed and excluded based
on locations of known endogenous virus, all hits occurring
at the same base, and/or VST matches to viral sequence. Of
the 468 BLAST matches, 66 map to the locations of 16
endogenous proviruses or virus-like LTR sequences; thus,
402 VSTs identify potential tumor-speciﬁc tags.
Identiﬁcation of CISs from these 402 VSTs was based
primarily on proximity of the insertions (average *25 kb)
but in some cases it also included Southern blotting to
conﬁrm that rearrangements were tumor speciﬁc, a char-
acterization of aberrant expression of genes at the locus,
and/or concurrence with previously identiﬁed loci. When
VSTs surrounded a single gene but were spread over
longer distances, we designated the site as a single CIS
(e.g., Evi16; Table 3). We identiﬁed 49 CISs that were
ranked with high conﬁdence because they have multiple
hits in our AKXD tumors (Table 3). When a CIS unique
to this screen was deﬁned by multiple insertions, we
designated the CIS a lymphoid viral insertion site (Lvis).
Loci previously identiﬁed in other screens are named in
accordance with the published nomenclature. We identi-
ﬁed 25 VSTs in a second class of loci consisting of single
insertions that identify CISs previously identiﬁed in
screens of other tumors (Table 4). The 74 CISs are dis-
tributed across the entire mouse genome and lie in or near
known proto-oncogenes and TSGs, in the vicinity of
candidate TSGs and proto-oncogenes, and near a set of
predicted genes.
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(VISION) Database
We have constructed a public internet-based graphical
database that provides speciﬁc information on VSTs,
including genomic locations, VST sequence, tumor typing
and histopathology, insertion-proximal genes, and pathway
analysis. Users can use the graphic view to browse CISs by
chromosome, viewing distance and orientation of genes
with links to additional gene information from Ensembl,
and Biocarta pathway information. Users can access pri-
mary VST sequence data, histopathology results, and
molecular tumor-typing information by clicking on the red
vertical bars representing individual VSTs in the graphic
view (Fig. 1B), or by clicking on the VST name in the list
view. The list view allows sorting of VSTs by chromosome,
tumor type, accession number, or VST name, as well as
links to individual VST records. The database can be
accessed at http://www.mouse-genome.bcm.tmc.edu/vision.
VST sequences are also available in GenBank and the
RTCGD (http://www.rtcgd.abcc.ncifcrf.gov/) to make
these data as widely available as possible.
Estimation of false-positive rate and degree of
saturation
MuLV insertions can occur in any chromosome in a
sequence-independent manner, but MuLV exhibits a slight
preference for insertions near transcriptional start sites and
CpG islands (Lewinski et al. 2006; reviewed in Wu et al.
2003). In vitro studies indicate that chromatin conforma-
tion also inﬂuences target site selection (Muller and
Varmus 1994; Pryciak and Varmus 1992; Pryciak et al.
1992). The identiﬁcation of false positives is possible
through the sequencing of clonal mutations that have no
association with cancer initiation or progression. Compared
to positively selected oncogenic mutations, these uninfor-
mative insertions are less likely to occur in the same locus
in independent tumors. False-positive CIS identiﬁcation
rates have been estimated by several different methods.
Random insertion based on genome size estimates the rate
of false-positive detection of cancer loci deﬁned by two
proviral insertions in a 26-kb window as one common site
in 250 VSTs distributed randomly in the genome (Mikkers
Table 1 AKXD mouse, tumor, and VST information by strain
Statistics Total AKXD strain
AK-2 AK-3 AK-9 AK-10 AK-13 AK-14 AK-16 AK-18 AK-27
Animals aged 469 32 96 32 29 58 14 71 63 74
Lymphomatous animals 204 7 57 18 4 18 4 13 42 41
% Tumor incidence 43 22 59 56 14 31 29 18 67 55
VST distribution
in high-conﬁdence CISs 140 6 18 13 1 21 2 6 30 43
in single-hit CISs 25 0 5 1 050347
single hits 237 13 53 18 7 28 6 25 40 47
with no BLAST hits 28 2 8 1 050039
repeat sequence hits 120 2 30 19 1 21 2 6 10 29
endogenous site hits
1 6 6 5 2 1 1 1 01 3 2527
total identiﬁed 616 28 135 63 9 93 12 45 89 142
Number of animals aged, tumor incidence, and the number of VSTs varied by strain. VST data are broken down by results of genomic alignments
and clustering analysis. VSTs that gave no signiﬁcant BLAST result or mapped to repeat sequences were excluded from further study. Signiﬁcant
BLAST results were analyzed for clustering and multiple hit CISs were constructed. Several multiple-hit CISs were excluded as likely
endogenous insertion sites. The remaining nonclustering single hits were compared to other viral mutation cancer screens to identify single-hit
CISs (single hits in this screen that map to the location of previously identiﬁed CIS)
Table 2 Distribution of tumors collected from AKXD mice
Tumor type %
B cell 27
Pre-B cell 21
Progenitor 15
T cell 13
Pre-T cell 1
Mixed B/T cell 13
Myeloid 4
Undetermined 6
Almost half of the tumors (48%) type as B cell or pre-B cell.
Molecular cell type was determined by histopathology and Southern
blot of IgH, IgK, Jb1, and Jb2 genes to detect somatic recombination
in lymphoid tumors
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are false positive (16.3 simulations/95 detected) using 1200
random insertions (Suzuki et al. 2002; supplemental).
Experiments using MuLV in immortalized human cervical
cell lines estimate as high as two thirds of two-hit CISs are
false positive (Wu et al. 2006). With such a wide variation
in estimates, we found it necessary to address this point.
Using experimental data, we ﬁrst calculated the detec-
tion efﬁciency of VISA by comparing VSTs recovered by
VISA to screening by Southern blot hybridization for
clonal proviral insertions, a more thorough but lower-
throughput method of insertion detection. We recovered an
average of 2.7 VSTs per tumor by the VISA method (550
nonendogenous VSTs/204 tumors). Previous analyses
showed that 1–10 somatically acquired proviruses can be
detected by Southern blotting in these tumors (data not
shown). Screening by Southern blot at eight loci yielded
several insertions not detected by VISA, showing that our
VISA tagging identiﬁed approximately 49% (24/49) of the
insertion events at these sites. This allows us to estimate an
average of 5.5 somatic proviral insertions per tumor (2.7
VSTs/49% detection rate). Using the 550 nonendogenous
VSTs (including hits in repeat sequence and hits with no
BLAST match), we calculate 1122 potential VSTs (550/
49%). By isolating cancer rates due to viral insertion, we
calculate that there are between 186 and 1020 true-positive
VSTs in the pool of 1122 total (based on 1–5.5 proviral
insertions required for tumor formation; see Materials and
methods section), so 17–91% of the 550 collected VSTs
identify true-positive cancer-associated VSTs. The lower
end of this range represents an average of 1 viral insertion/
tumor required to cause cancer and the upper end repre-
sents an average of 5.5 insertions/tumor required to cause
cancer. These 550 nonendogenous VSTs were narrowed to
165 VSTs at 74 loci by clustering analysis, representing a
dramatic minimization of false positives.
Calculations of mutagenic saturation provide a rough
estimate of the completeness of a data set. Modeling
insertion frequency with a Poisson distribution estimates
that 9–42% of the readily identiﬁable loci have been
identiﬁed by at least a single insertion (see Materials and
methods section). This is a low degree of saturation and ﬁts
with the low degree of overlap with other screens, low
multiplicity of insertion at CISs, and a high degree of
unique data from this study. This calculation of saturation
does not account for variability in insertion efﬁciency at
different loci and may not accurately predict the number of
oncogenes in hematopoietic cells. However, the calculation
does provide an estimate of the number of sites likely to be
identiﬁed by retroviral insertion in the AKXD strains used
in this screen and what proportion have been identiﬁed by
our VST screen.
Expression of genes ﬂanking proviral insertion sites
In many instances there are a number of genes in the
vicinity of a speciﬁc CIS with one, and possibly more,
being affected by the proviral integration event. Retroviral
insertions are known to alter gene expression at distances
Fig. 1 A VISA screening
yields the exact base pair of
insertions. The VSTs that deﬁne
Evi1 are shown aligned by
CLUSTAL W to illustrate VST
clustering analysis. VST
sequences are generated from
ampliﬁcation from a restriction
enzyme site (underlined)
anchored genomic primer and a
virus speciﬁc primer. The start
of proviral sequence (shown in
bold) marks the exact base of
viral insertion. B Clustered
VSTs are displayed graphically
in the VISION database with all
annotated candidate genes
within 200 kb of any insertion.
A screen capture of the Notch1
locus is shown here for
illustration
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VST hits
a S
b Chr Designation
c Candidate genes
d Tumor type
e
2, 2s 2 1 Evi32 Prdm14, Ncoa2, ENSMUSG00000062226, Slco5a1 T/B(2)
4, 1s, 1r 1 Lvis10 Wdfy1*, Mrpl44, serpine2, Ap1s3 B, pT, pB
2, 2r 1 Sag Sag, 5830472F04Rik, Usp40, Atg16l1 pB
21 Lvis11 Arl7, Glrp1 B, T
21 Lvis12 Jarid1b/Plu1*, Rabif, Klhl12, Adipor1 T, pro
3, 4s, 2m 2 Notch1 Notch1*, AU024582, Inpp5e, Egﬂ7 T(2), T/B
11 2 Lvis5 Alx4* B
22 Lvis13 Pofut1*, Asxl1*, Kif3b, 8430427H17Rik pro,T/B
33 Evi1 Evi1* pro(2), B/M
3, 3s, 1h 3 Evi53 1700021C14Rik, Cct3, Rhbg, 0610031J06Rik pB(3)
5, 5s 3 Evi54 Notch2, NP_001028951.1*, Adam30, Sec22b pB(2), pro, B
2, 1s 3 Nras Nras*, CSDE1_MOUSE, 5730470L24Rik, Ampd1 pro, pB
2, 1r 3 Lvis14 Mcoln2*, Mcoln3, Edg7, Wdr63 B(2)
2, 2r 4 Fgr Fgr*, Adhc1, Q3U0Y7, ENSMUSG00000073749 T/B(2)
4, 7s,15m, 3h 5 Gﬁ1 Gﬁ1*, Glmn, AW060207, Evi5 B(2), pB, T
2, 1r 6 Lvis15 Tcf3*, Retsat*, Rbed1, Tgoln1 B, pro
76 Lvis16 Rassf8, Tuba7, Bhlhb3, Sspn B(3), T(2), pB, pro
37 Lvis17 Ceacam1*, Erf, Cic, BC024561 pB, B/M, M
5, 4s, 3m 7 Evi84 (Lvis2) Rras2, Spon1, Copb1, Psma1 B(2), T(2), pro
2, 2s, 1h 7 Ccnd1 Ccnd1, Oraov1, Fgf15, Fgf4 pB, T
2, 2s, 4r 8 Rasa3 Rasa3*, 1700029H14Rik, Gas6, ENSMUSG00000057052 pro(2)
2, 1r 8 Lvis18 Cdyl2, Dynlrb2, ENSMUSG00000074073p B
28 Lvis4 (Ris2) Cbfa2t3h (ETO-2), Ris2, Aprt, Galns pB
2, 1h 9 Lvis19 Btg4, Snf1lk2, Layn, Pou2af1 B, pro
2, 1h 9 Sh3bgrl Sh3bgrl2, Elovl4, Ttk pB(2)
2, 2s, 1m 9 Evi100 Ccr4, Cnot10, Q8C888_MOUSE, Glb1 pB, B
1, 1h 1 11 Lvis7 4933435A13Rik, Rel, Pex13, Papolg pB
2, 3s 0 11 Evi108 Smg6*, Hic1, Ovca2, Srr pro, pB
2, 7r 11 Ccr7 Ccr7*, Smarce1, 6330509G02Rik, Tns4 pB, B
2, 2r 11 Lvis20 Map3k14*, 1700023F06Rik, Arhgap27, Hexim1, Hexim2 B(2)
3, 1s 12 Nmyc1 n-Myc1(Mycn), ENSMUSG00000066629 T(2), B
2, 2r 12 Pnma1 Pnma1, ENSMUSG00000042962, ENSMUSG00000072946,
ENSMUSG00000042507
B, T
31 2 Lvis21 Chga, Itpk1*, Golga5, Moap1 pro, pB, T/B
2, 1s, 1r 12 Lvis22 Bcl11b*, ENSMUSG00000072842, Setd3, Ccnk pro, T
31 2 Lvis23 Igh6, Tmem121, Gm900, 4930427A07Rik pro
12, 55s, 8h 13 Evi16 (Lvis3, 9) Sox4, XP_914375.1 pro(3), pB(2), B(2), T(2), T/B, M
2, 2r 13 Auh Auh*, ENSMUSG00000065771, Nﬁl3, Syk pB, T/B
3, 4s 15 Myc Pvt1, Myc, ENSMUSG00000056590 pro, pB, B
1, 1r 4 15 Lvis24 Tnfrsf13c(Baffr) pB
21 7 Lvis25 XM_001005577.1, XM_001001995.1, XR_004526.1 T(2)
21 7 Ccnd3 (Lvis8) Ccnd3, Bysl, Trfp, Usp49 pB, B
6, 5s 2 18 Evi3 Evi3 pB(5), pro
2, 1s, 1r 18 Lvis26 Cxxc5*, 2610307O08Rik*, XP_913389.2, 1700066B19Rik T, B
2, 1r 18 Lvis27 Malt1, Alpk2, ENSMUSG00000057009, ENSMUSG00000065402 pro, M
2, 2s 18 Evi138 Nfatc1, Atp9b, Ctdp1 pro, pB
31 9 Lvis28 Ighmbp2, Saps3, Gal, Mtl5 T/B
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123of over 50 kb (Hansen and Justice 1999b; Jonkers and
Berns 1996), so the analysis of gene expression in tumors
allows for the validation of candidate genes and a deter-
mination of whether insertions upregulate or downregulate
expression of the ﬂanking genes. We selected 16 candidate
genes with one or more proximal insertions at nine dif-
ferent loci to test expression by real-time quantitative PCR
(QPCR). The loci were selected based on the presence of
interesting candidate genes. Several genes were selected
based on their association with the Notch signaling path-
way (Notch1, Notch2, Pofut1, Psen1, Numb, Lfng, Dtx2,
ADAM precursor, and ADAM 3, 9, 19, 32) or because they
map in close proximity to Notch genes (Egﬂ7). The
remaining genes were selected because they were sites of
very high numbers of insertions (Sox4, rRas2, and Copb1).
Nineteen tumors with insertions and two control nontumor
AKXD tissues were assayed for expression of all 16 genes.
Three of four CISs showed signiﬁcant upregulation of one
or more proximal genes and two of ﬁve single insertions
showed upregulation. Signiﬁcant upregulation of gene
expression generally correlated with the presence of
insertions proximal to the upregulated gene, particularly at
CISs (Fig. 2). In some cases we found genes to be upreg-
ulated without proximal insertions. This could be due to
failure to detect a proximal insertion or mutation of another
gene in the pathway that led to upregulation.
Discussion
Using VISA, we identiﬁed the genomic sequences ﬂanking
somatically acquired proviral insertions in tumors from
nine AKXD RI strains that develop a high incidence of B-
cell or mixed B/T-cell leukemia and lymphoma. The VISA
technique has an advantage over PCR techniques that
require a subcloning step because PCR products are
sequenced directly, reducing the likelihood of sequencing
contaminating products. Furthermore, because a rare PCR
product is not likely to be subcloned and sequenced, such a
technique focuses on proviral insertions that are mono-
clonal in the tumor population and, therefore, are likely
cause tumor formation. Analysis of the cellular sequences
allowed us to identify 74 loci that identify one or more
candidate proto-oncogenes or TSGs.
Assessing data quality was a priority, with reports of
potentially high rates of false-positive CISs (de Ridder
et al. 2006; Wu et al. 2003). In AKXD mice, viral inte-
gration is the primary mutagen contributing to cancer
formation. Base cancer rates from AKXD-20 mice that lack
a transposable AKV virus were compared to rates from
AKXD mice containing active virus in this study, allowing
us to calculate that 91% of cancers in these AKXD mice
are causally associated with at least one viral insertion. Of
our 550 nonendogenous VSTs, we calculate 17–91%
identify true-positive CISs. This range is dependent on the
average number of true-positive insertions required to
cause cancer, with 17% (true-positive percentage) of 550
VSTs representing a situation where only one viral inser-
tion per cell on average was required to cause cancer. To
reduce the false-positive rate, we used clustering of inser-
tions to identify cancer-associated loci. If insertions are
identiﬁed at the same locus in independent tumors, they are
more likely to be a result of positive selection and repre-
sentative of oncogenic mutations. Clustering analysis
reﬁnes the pool of 550 VSTs to 165 VSTs, reducing the
false-positive rate. These 165 VSTs represent 74 frequent
Table 3 continued
VST hits
a S
b Chr Designation
c Candidate genes
d Tumor type
e
11, 23s, 1h 15 19 Lvis1 Hex, Exoc6, Eg5, Ide B(4), pB(2), T/B(2), pro, M, pT
2, 1r 19 Lvis29 Wnt8b, Scd1-4, Chuk (Ikka) pro, pB
3, 1r X Lvis30 Tlr7, Tlr8, ENSMUSG00000072409, Tmsb4x pB, pro, B
VST sequences were mapped to the mouse genome by BLAST and cosegregating hits are listed as common sites
a # hits column lists the number of VSTs that map to the locus from this screen (no label) and the number of hits at this locus published in Suzuki
et al. (s), Mikkers et al. (m), Shin et al. (h), or other hits from the RTCGD (r)
b Southern blotting of tumor DNAs revealed insertions not detected by VISA
c Previously described loci are named consistently with the literature. Novel loci are named Lvis #
d Up to four candidate genes proximal to insertions are listed for each locus. Predicted transcripts and ESTs are listed as Ensembl, Riken,
UniProtKB/TrEMBL, or Refseq designations. An asterisk (*) following the transcript name indicates that an insertion lies within the transcript.
Best candidates (closest gene or known function) are listed ﬁrst
e Tumor cell type is presented as tumor type letter code followed by the number of tumors of that type, if more than one, in parenthesis. T = T
cell; B = B cell; T/B = mixed T and B cell; M = myelod; E = erythroid; pB = pre B; pT = pre T; pro = progenitor. A. High conﬁdence hits were
chosen based on VST clustering, concurrence with established loci, Southern blotting, and expression information. B. Several single hits in this
screen coincided with common sites from other screens
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123insertion loci selected for oncogenicity. To reconcile these
observations with the high observed false-positive rate in
immortalized human cervical cell lines (Wu et al. 2006),
we have only to point out that as cancer-associated inser-
tions are positively selected, insertions that are not
associated with cancer are negatively selected, reducing the
background false-positive rate. Because every sample
analyzed here was cancerous, we have enriched for inser-
tions causing cancer, reducing the number of ‘‘random’’
insertions and the false-positive error rate. Furthermore, the
degree of saturation of our VST detection indicates that we
have likely not identiﬁed each of the CISs causative of
cancer in this lymphoid tumor bank.
A comparison to similar screens in other mice (Mikkers
et al. 2002; Shin et al. 2004; Suzuki et al. 2002) indicates
that the CISs identiﬁed in our study are likely to be inﬂu-
enced by differences in genetic background. We compare
our data to the screen described by Suzuki et al. (2002)
because it was of similar scale, included AKXD RI strains
and lymphoid neoplasms, and neither screen was based on
a known sensitizing mutation. The Suzuki screen identiﬁed
493 tags at 152 CISs, whereas we identiﬁed 140 tags at 46
CISs. As a measure of saturation, allele frequencies for
CISs (number of insertions/number of loci) in our VST
screen were comparable to the Suzuki screen: 3.04 (140/
46) (this article) vs. 3.24 (493/152) (Suzuki et al. 2002).
One would expect to ﬁnd a much greater allele frequency/
saturation with more CIS tags when screening the same
number of possible cancer loci. The discrepancies between
the two screens for allele frequency and number of sites
identiﬁed can be partially explained by the number of
different strains used for each screen and strain genetic
background. Target site preferences of provirus have been
shown to vary among mouse strains and among AKV
subtypes (Martin-Hernandez et al. 2006). Our screen used a
subset of AKXD strains that are susceptible to B-cell
neoplasms and the Suzuki screen used more AKXD strains,
fewer aged mice per strain, and NFS.V+ and BXH2 RI
mice. It is likely that strain variations, particularly predis-
posing mutations in individual AKXD strains, are
inﬂuencing the pool of alleles recovered in common.
Therefore, the calculated saturation is measuring primarily
Table 4 CISs with one tag in our database
VST hits Chr Designation Candidate genes Tumor type
1, 1m 1 Cis1 ENSMUSG00000067125, ENSMUSG00000026238, 1700019O17Rik, Pde6d B
1, 3s, 17m 2 Bmi1 Bmi1*, Commd3, BC061194, XP_895476.1 pB
1, 7s, 3m, 1h 2 Evi18
1 XP_984911.1, Spred1, ENSMUSG00000065794, Rasgrp1 pro
1, 7s, 3m, 1h 2 Evi18
1 Rasgrp1, 2610510H03Rik, ENSMUSG00000065845, XR_002866.1 T/B
1, 3s 2 Evi47
1 Hck*, Pofut1, Asxl1, Plagl2 pB
1, 2s 2 Evi50 Gnas*, ENSMUSG00000060124, ENSMUSG00000067549, ENSMUSG00000065410 B
1, 6s, 2h 4 Evi59 Bach2, ENSMUSG00000073980, Gja10, ENSMUSG00000073981 T
1, 2s 4 Evi162 Q6R5H0_MOUSE, Klf4 B
1, 2s 4 Evi62 Cnr2, Fuca1, Pnrc2, Fusip1
1, 1h 4 Evi11 Rpl11, Id3, E2f2 pro
1, 4s 5 Evi29 Card11*, Gna12, 6530401C20Rik T
1, 3s 6 Evi80 Lrmp*, Casc1, 4930469P12Rik, Kras B
1, 6s 7 Evi24 Gmfg, Lrfn1, Samd4b, Paf1 pro
1, 2s 8 Evi88 Tacc1, Plekha2, XP_988283.1, Tm2d2 T/B
1, 2s 8 Evi96 Foxf1a, Mthfsd, Foxc2, NM_008024.1 B
1, 1m, 1h 10 Txnrd1 1700028I16Rik*, Nfyb, Txnrd1, Hcfc2 pB
1, 1m 11 Evi106
1 1110064P04Rik*, ENSMUSG00000073112, ENSMUSG00000065591, 1700093K21Rik pB
1, 1m 11 Evi106
1 Rel, 4933435A13Rik, Papolg, Pex13 pB
1, 2s, 1m 11 Evi159 Rnf43*, Supt4h1, ENSMUSG00000065420, Bzrap1 pB
1, 1m 11 Cis11 Stat5b*, Stat5a., D11Lgp1e, Hcrt pB
1, 1m 13 Cis13 Dusp22, Uqcrfs1, Irf4, Exoc2 B
1, 9m 17 Pim1 Fgd2, Mtch1, Pi16, Pim1 B
1, 2m 19 Dkmi29 Cd5, A430093F15Rik, Vps37c, Cd6 pro
1, 2m X Pim2 Hdac6, Gata1, Eras, Pcsk1n pro
1, 1m X Nki37 Suhw3, Slc25a14, Rab33a, Gpr119 pro
Twenty-four single-hit VSTs identiﬁed established CISs. Table information same as Table 3; see footnotes. 1. For Evi18 and Evi106, VSTs fell
on either side of the established locus (within 200 kb) but VSTs were[200 kb apart and are listed as separate CISs
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123the mutation of loci that cooperate with existing cancer-
predisposing mutations in these strains, rather than all
possible cancer loci.
Additional comparisons between the two screens
showed that only 15 of the 46 multihit CISs were identiﬁed
as CISs in the previous screen. Low overlap between the
screens suggests that many oncogenes and TSGs identiﬁed
at these CISs will be unique to this AKXD tumor subset.
Except for hits at the Lvis1 and Sox4 loci, the allele fre-
quency was nearly the same for the remaining 14 shared
loci with 3.15 (41/13) insertions/locus in our screen vs.
3.46 (45/13) in the Suzuki screen, indicating similar levels
of saturation. This also demonstrates that Suzuki et al.
(2002) were sampling from a larger pool of mutations
because they found very similar mutation frequencies for
most targeted genes that were common between the
screens, yet they mapped more than twice as many
sequence tags. The implication of this ﬁnding is that these
screens are identifying cancer loci that cooperate with
predisposing cancer loci carried in these genetic back-
grounds at a high rate while identifying all blood cancer
loci at a lower rate. This also raises the possibility that
strain-speciﬁc germ line insertions may be acting as sen-
sitizing mutations, inﬂuencing the frequency with which
speciﬁc loci are identiﬁed as well as the occurrence of
speciﬁc tumor types.
Another measure of the quality of the data is the ability
to replicate previous work and to identify validated onco-
genes. As expected, many of the insertional mutations
identiﬁed CISs that were known from previous screens,
including Evi1, 3, 11, 16, 32, 38, 53, 54, 84; Lvis1-9; Myc,
N-Myc, Ccnd1, Ccnd3, Ris2, Nras, Notch, and Gﬁ1 (Han-
sen and Justice 1999a; Hansen et al. 2000; Li et al. 1999;
Mikkers et al. 2002; Mucenski et al. 1988a; Shin et al.
2004; Suzuki et al. 2002). This validates the VISA method
for identiﬁcation of CISs; however, the most interesting
data are the 21 loci not previously identiﬁed as CISs. These
sites may be speciﬁc to a lymphoid subset of tumors, and,
in particular, many may be unique to the B-cell lineage.
Several of these novel sites have been validated as novel
cancer-causing genes by gene expression in tumors or by
oncogenicity after bone marrow transductions, or in
transgenic mice, including Hex (George et al. 2003), Evi3
(Hentges et al. 2005), Tnfrsr13c (Hentges et al. 2002), Evi1
(Boyd et al., 2006), Sox4 (Boyd et al. 2006), and Eg5
(Castillo et al., unpublished). Of note, the Lvis24
(Tnfrsf13c) site was ﬁrst detected as only a single hit in our
VST database, but was pursued because it was commonly
Fig. 2 Misregulation of genes proximal to insertion loci. A set of 16
genes at 9 loci (4 CISs, 5 single hits) with proximal insertions was
tested by real-time QPCR for misregulation in 19 tumors bearing
those insertions and 2 control tissues. Tumors are labeled according to
the organ of origin (mLN = mesenteric lymph node; LN = axillary,
cervical, and/or branchial lymph nodes). Only genes that displayed
signiﬁcant misregulation are displayed here. Three CISs assayed
(Notch1, Notch2, Ras/CopB1) showed misregulation of at least one
proximal gene, two of the ﬁve single hits showed signiﬁcant change
of one gene. Real-time PCR threshold cycle (Ct) readings were
normalized for cDNA content comparison to the average Ct of 16
genes assayed for each tumor using the formula: DCt = (Ctsample)-
(CTavg. for tumor). To normalize scale across several genes, fold change
relative to average DCt for each gene across all tumors (except tumors
with insertions near the gene) was calculated using the equation: fold
change = 2
(DCtavg. for gene)-( DCtsample). To determine signiﬁcant changes in
gene expression, the average and standard deviation of normalized
values were calculated for each gene across all tumors. Values on the
table are expressed as the number of standard deviations from the
mean of fold changes for each gene. The shaded box designates –1 to
+1 standard deviations. Values outside this box are considered
signiﬁcant. Black arrows denote signiﬁcant misregulation of genes in
tumors harboring insertions near the misregulated genes. rRas2 and
Copb1 are at the same locus and most insertions fall between the two
genes
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123overexpressed in human lymphoid tumors in the Cancer
Genome Anatomy Project (CGAP) database, showing that
some unclustered single insertions are true positives.
The Lvis1 site is the most frequently rearranged locus in
this tumor subset, with retroviral insertions detected in 26
independent tumors. Subsequent tests of gene expression
showed that that although the insertions occurred 50 kb
distant of the hematopoietic transcription factor Hex, they
upregulated the expression of Hex as well as the kinesin-
related spindle protein Eg5. Subsequently, both genes have
shown oncogenicity in bone marrow transductions (George
et al. 2003) or transgenic mice (Castillo et al., unpub-
lished), indicating that retroviral insertions may inﬂuence
the expression of two or more oncogenes at a single site
and affect genes more than 50 kb distant. Such an obser-
vation led us to develop the VISION database such that all
genes in the region of the proviral insertions are displayed,
rather than indicating only the closest gene to the retrovi-
rus. Similarly, all genes in the region of the proviral
insertion site are listed in Table 1 because any or all of
them are candidate proto-oncogenes.
Histologic analysis reveals that this tumor collection is
composed of primarily lymphoid tumors; therefore, we
would expect to identify known or suspected proto-onco-
genes and TSGs implicated in B-cell lymphomagenesis
and/or normal B-cell differentiation. Indeed, several genes
of this type are identiﬁed, including Bcl11b (Cismasiu et al.
2006), Plu-1 (Lu et al. 1999), Atp1b1 (Chen et al. 2006;L e
Page et al. 2006), Blzf1/Jem1(Duprez et al. 1997), Ccr4
(Yoshie et al. 2002), Ccr7 (Albert 2006), Ceacam I and II
(Obrink 1997), and Traf1 and Malt1 (Nakagawa et al.
2005). Many of these have been implicated in lymphoma
development by virtue of aberrant expression in tumors or
as targets of translocation in human cancers. Finding these
genes not only provides support for the validity of our
methods but it also provides further evidence that these
genes are a cause rather than a consequence of cancer. In
some cases several genes that are known to function within
an established or proposed signaling pathway were iden-
tiﬁed in our screen. Insertions identifying genes that act
within oncogenic pathways support a functional interaction
and delineate pathways involved in cancer.
The ﬁrst such pathway is the Notch signaling pathway.
Several members of the Notch pathway are identiﬁed as
candidates, including Notch1, Notch2, Dtx2, Lfng, Psen1,
Numb, Pofut1, Tcf3/E2A, and ADAM3, 5, 9, 18, and 32.W e
ﬁnd insertions not only near Notch1 (a regulator of E2A
and EBF) (Smith et al. 2005) and E2A, but also in Evi3,
which modulates EBF activity (Hentges et al. 2005).
Insertions in E2A/Tcf3 lie within the gene, which may
indicate a loss of function followed by loss of heterozy-
gosity. This is consistent with the ability of Notch1 to
repress E2A activity and the observed upregulation of
Notch1 in tumors. Cbfa2t3h (ETO-2) is 75% identical to
ETO, which is a frequent target of translocations (with
AML1) in humans. The resulting AML-ETO fusion protein,
like Notch, inhibits E protein activity (Plevin et al. 2006).
Independent of AML-ETO fusions, ETO itself is able to
inhibit E-protein-dependent transactivation activity (Zhang
et al. 2004). Likewise, ETO-2 binds SCL (a T-ALL
oncoprotein) in a complex that inhibits E-protein activity.
SCL also binds GFI1B (Schuh et al. 2005), the functional
equivalent to Gﬁ1 in blood cells (Fiolka et al. 2006). Gﬁ1 is
a frequent target of insertions in this screen and is the
homolog of the Drosophila gene senseless, a modulator of
Notch signaling (Nolo et al. 2000). Not only do we observe
frequent insertion near Notch signaling genes, but these
genes are misexpressed in the cancers. QPCR was used to
assess expression levels of several candidate genes,
including several Notch signaling genes, where Notch1,
Notch2, Numb, and Pofut all showed signiﬁcant upregula-
tion (Fig. 2). Associations between these genes are
illustrated in Fig. 3. Mutation of many genes that affect
Notch signaling and E protein signaling identiﬁes these
pathways as common and powerful routes to cancer in
blood cells.
NFjB signaling is frequently involved in proliferation
and survival signals of many blood cell lineages. NFjB
signaling genes Ikka/Chuk, Malt1, and Traf1 were identi-
ﬁed by multiple insertions in this screen. MALT1, IKKB,
and IKKA/CHUK form a complex that is able to activate
NFjB signaling in T and B cells (O’Mahony et al. 2000;
Wegener et al. 2006; for review see Thome 2004). TRAF1
is able to activate NFjB during B-cell activation via CD40
but may have many roles in lymphoid development (Xie
et al. 2006; for review see Lee and Lee 2002). These data
indicate that aberrant activation of NFjB contributes to
lymphoid cancer and that other members of this pathway
are potential oncogenes.
Evi1 was originally identiﬁed through viral mutagenesis
as a myeloid oncogene (Mucenski et al. 1988b). A screen
for targets of EVI1 transcription factor activity yielded
several candidate genes, including Map3k14 (Yatsula et al.
2005). Our screen identiﬁed three insertions near Evi1 and
two insertions near Map3k14, suggesting a functional
pathway for Evi1 and Map3k14 in cancer.
A pair of related genes, Hck and Fgr, were identiﬁed as
candidate oncogenes by this screen. Notably, both of these
Src family kinases are used for b-integrin outside-in sig-
naling (Giagulli et al. 2006). In acute myeloid leukemia
blasts, the expression of FGR and HCK is associated with
early commitment and differentiation of myeloid lineages
(Willman et al. 1991). These molecules are also critical for
pre-B ALL induction by BCR/ABL (Hu et al. 2004).
Furthermore, comparative genomic hybridization showed
ampliﬁcation of FGR in endometrial cancer (O’Toole et al.
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1232006). The somatic mutations found in the Fgr and Hck
loci provide additional evidence linking downstream sig-
naling of these two genes to cancer. The preceding
pathways are all normally involved in proliferation or
differentiation of lymphoid lineages, lending further
validity to their identiﬁcation as oncogenes or TSGs in a
primarily lymphoid cancer collection.
The screen of the lymphoid tumors described here pro-
vides a new collection of 21 loci that are associated with
leukemia and lymphoma. The majority of tumors recovered
were of B-cell origin, indicating that the loci are identify-
ing genes involved in normal B-cell development and,
when expressed aberrantly, in cancer. Indeed, many of the
genes identiﬁed are B-cell-speciﬁc genes with known
functions in development and maturation. Insertions near
several members of multiple pathways identify networks of
signaling active in the development and progression of
blood cancers. Notably, members of the Notch signaling
pathway were frequently identiﬁed and, for some, dereg-
ulated expression was veriﬁed by QPCR. The identiﬁcation
of signaling networks active in cancer will allow us to
understand cancer as a misregulation of cell processes
rather than a collection of mutations leading to a pheno-
type. This is particularly useful for the evaluation and
prioritization of drug targets and the development of
effective treatments for disease.
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